

LEGAL INFORMATION

Last updated: as of 15 of December 2018

Ref No.	Description	Comments
1	The exact name of the issuer and the issuer's predecessor (if any)	Solve.Care Foundation OÜ
2	The address of the issuer's principal executive offices	Narva mnt 5, Tallinn 10117, Estonia
3	The exact title and class of the security	SOLVE Tokens, no class or title apply
4	The par or stated value of the security	N.A.*
5	The number of shares or total amount of the securities outstanding as of the end of the issuer's most recent fiscal year	Total number of Solve Tokens issued: 350M
6	The name and address of the transfer agent, corporate secretary, or other person responsible for transferring shares and stock certificates (if applicable).	N.A.
7	A statement of the nature of the business of the issuer and the products and services it offers, the nature and extent of the issuer's facilities, which shall be presumed reasonably current if the statement is as of 12 months before the transaction date.	<p>Solve.Care Foundation OÜ builds, licenses and operates a healthcare administration platform designed for use by patients, employers, physicians, healthcare agencies, and insurance companies (the "The Solve.Care Platform").</p> <p>The Solve.Care Platform uses blockchain technology as the underlying distributed ledger for managing care events between patient, doctor, pharmacy, laboratory, insurer, and other parties.</p> <p>Patients are empowered to manage their healthcare decisions. Employers can use the platform to administer benefits, reduce costs, and reward their employees. Physicians and hospitals can issue prescriptions, manage appointments, and coordinate with a specialist.</p> <p>The goal of the Solve.Care Platform is to coordinate care across all stakeholders, eliminate inefficient processes and improve health outcomes while reducing cost for all parties involved.</p>

8	The names of the officers and directors of the issuer	Mr. Pradeep Goel, CEO
9	The names of any persons registered as a broker, dealer, or agent that shall be paid or given, directly or indirectly, any commission or remuneration for such person's participation in the offer or sale of the securities and any affiliation with the issuer	N.A.
10	The issuer's most recent balance sheet and profit and loss statement and similar financial statements, which shall—	The Company was incorporated in 31.08.2017. No financial statement has been created or issued so far. The first annual report to be submitted in June 30, 2019.
	a) be for such part of the 2 preceding fiscal years as the issuer has been in operation;	N.A.
	(b) be prepared in accordance with generally accepted accounting principles or, in the case of a foreign private issuer, be prepared in accordance with generally accepted accounting principles or the International Financial Reporting Standards issued by the International Accounting Standards Board;	N.A.
	(c) be presumed reasonably current if—	N.A.
	(i) with respect to the balance sheet, the balance sheet is as of a date less than 16 months before the transaction date; and	N.A.
	(ii) with respect to the profit and loss statement, such statement is for the 12 months preceding the date of the issuer's balance sheet; and	N.A.
	(iii) if the balance sheet is not as of a date less than 6 months before the transaction date, be accompanied by additional statements of profit and loss for the period from the date of such balance sheet to a date less than 6 months before the transaction date.	N.A.
11	To the extent that there is a potential seller who is a control person (such as an officer, director or 10% beneficial owner) with respect to the issuer, a brief statement regarding the nature of the affiliation	Mr. Pradeep Goel is the sole shareholder

* N.A. – means not applicable